Reading ENSC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENSC free→Reading ENSC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENSC free→QuarterlyIQ Insights · ENSC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing On May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is subject to delisting unless it submits a plan withi…
Results of Operations and Financial Condition. On May 15, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor will t…
Entry into a Material Definitive Agreement. As previously reported in a Current Report on Form 8-K filed on November 17, 2025, on November 13, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) directly with an institutional investor (the “ Purchaser ”). On April 6, 2026 (the “ Closing Date ”), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 sha…
Based in part upon the representations of the Purchaser in the Purchase Agreement, the offer and sale of securities in the Offering are exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The offer and sale of the securities in the Offering have not been registered under the Securities Act or any state securities laws and the Securities may not…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On April 1, 2026, Ensysce Biosciences Inc. (the “Company”) received a resignation notice, dated and effective April 1, 2026, from Curtis Rosebraugh, a member of our Board of Directors. The text of the resignation notice is attached to this Form 8-K as Exhibit 17. Until his resignation, Dr. Rosebraugh served as a member of the Nominating and Corporat…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, Ensysce Biosciences Inc. (the “Company”) received a resignation notice, dated and effective March 24, 2026, of Lee Rauch, a member of our Board of Directors. The text of the resignation notice is attached to this Form 8-K as Exhibit 17. Until her resignation, Ms. Rauch served as a member of the Audit Committee and Compensation Com…
Results of Operations and Financial Condition. On March 30, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard On February 25, 2026, Ensysce Biosciences Inc. (the “Company”) received a notice (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. Nasdaq req…
Entry into a Material Definitive Agreement. On November 13, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) directly with an institutional investor (the “ Purchaser ”), pursuant to which the Company agreed to issue and sell in a registered direct offering (the “ Registered Direct Offering ”), (i) 1,513 shares (the “ Shares ”) of Series B Preferred Stock of the Company, par value $0.0001 per share (the “ Pref…
Other Events. On November 17, 2025, the Company issued a press release announcing the Registered Direct Offering and Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Forward-Looking Statements This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende…
Based in part upon the representations of the Purchaser in the Purchase Agreement, the offer and sale of securities in the Private Placement are exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The offer and sale of the securities in the Private Placement have not been registered under the Securities Act or any state securities laws and the S…
Results of Operations and Financial Condition. On November 14, 2025, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, n…
Results of Operations and Financial Condition. On August 13, 2025, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor will…
Changes in Registrant’s Certifying Accountant On June 3, 2025, Ensysce Biosciences, Inc., (the “Company”) was notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Company’…
Results of Operations and Financial Condition. On May 13, 2025, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor will t…
Based in part upon the representations of the Investors in the Inducement Agreements, the offering and sale of the Common Warrants is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Common Warrants by the Company in the Inducement Agreement and Private Placement and the Placement A…
Entry Into a Material Definitive Agreement On April 23, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into inducement offer letter agreements (the “ Inducement Agreements ”) with certain warrant holders for the exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company, par value $0.0001 per share (the “ Common Stock ”). The warrants were issued in March 2025 and have an exercise price of $3.24 per share. The…
Other Events. On April 23, 2025, the Company issued a press release announcing the Inducement Agreement and the Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Based in part upon the representations of the Investors in the Purchase Agreement, the offering and sale of the Common Warrants is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Common Warrants by the Company in the Private Placement and the Placement Agent Warrants have not been…
Other Events. On March 31, 2025, the Company issued a press release announcing the Registered Direct Offering and the Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Entry Into a Material Definitive Agreement On March 30, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into a definitive Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell in a registered direct offering (the “ Registered Direct Offering ”), (i) an aggregate of 239,594 shares (the “ Shares ”) of common stock of the Company, par value $0.0001 per share…
Results of Operations and Financial Condition. On March 10, 2025, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2024. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Entry Into a Material Definitive Agreement On January 15, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into a Product Development and Commercial Manufacturing Supply Master Services Agreement (the “ Agreement ”), dated as of January 12, 2025, with Galephar Pharmaceutical Research, Inc., a Puerto Rico corporation (“ Galephar ”). The Agreement provides for Galephar to expend up to $10 million (the “ Cap ”) to support research and development, manufacture, packaging and te…
Importance-ranked changes since the prior daily snapshot.
Management rose by 10.1 points (from 26.2 to 36.3).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.